Influx Healthtech (INFLUX) Q2 FY27 Revenue Plunges 42% Sequentially as Client Orders Slow
The nutraceutical manufacturer's September quarter revenue fell sharply from a high March quarter, though margins held steady amid cost cuts.
Influx Healthtech's Q2 FY27 revenue fell 41.8% sequentially to ₹85.4 crore, with profit down 41.5%. The steep decline follows a strong March quarter, with the company maintaining its net profit margin at 14.1%.
For a contract manufacturer like Influx Healthtech, quarterly revenue is a direct read on client order flows. The September quarter showed a sharp contraction, with sales falling 42% from the March period as brand owners pulled back.
The numbers tell a story of broad-based decline. Revenue dropped to ₹85.4 crore from ₹146.8 crore last quarter, and profit fell to ₹12.0 crore from ₹20.5 crore. The net profit margin held nearly flat, edging up 10 basis points to 14.1%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 |
|---|---|
| Period | Sep 2026 |
| Revenue (₹ Cr) | 85.41 |
| Profit (₹ Cr) | 12.01 |
| Net Profit Margin | 14.1% |
A High Base and Shifting Client Mix
The plunge is partly a base effect. The March quarter was exceptionally strong, with revenue of nearly ₹147 crore. Management had previously tempered its growth outlook, shifting focus from pure speed to a more profitable client mix.
According to a Tipsheet Markets report, the company walked back an earlier goal to double revenue by FY27. It now targets 25-30% growth for the full year, citing this strategic shift and facility ramp-up timelines.
Costs Fell in Step with Sales
Expenses dropped in line with the lower revenue, preserving margins. Employee costs fell 44%, depreciation was down 38%, and other income plunged 77%. This disciplined cost control kept the profitability ratio steady despite the top-line shock.
The company remains debt-free with a strong current ratio of 3.6, per the latest analysis. It is also deploying IPO proceeds for capacity expansion, including a new 75,000 sq ft nutraceutical facility.
The Capacity Waiting for Demand
The broader market context is not the problem. The Indian nutraceuticals sector is growing rapidly, with the vitamins and nutrition segment leading at 22% growth in September, notes an IANS report citing Equirus Securities data.
Influx Healthtech’s challenge is filling its own new capacity. The upcoming plant, expected to be operational, represents a 2.5x increase in installed space. The next few quarters will test its ability to convert this industry tailwind into firm client orders.
Key Points
- Revenue fell 42% sequentially to ₹85.4 crore, reflecting a slowdown in client orders from a high March quarter base.
- Net profit margin held steady at 14.1% as total expenses fell in proportion to the sales decline.
- Management has revised its FY27 growth target to 25-30%, prioritizing a profitable client mix over aggressive top-line expansion.
- The company is expanding capacity into a strong market, with the Indian nutraceutical sector showing over 20% growth in key segments.
Hexa Perspective
The quarter highlights the lumpy nature of contract manufacturing revenue. The steep sequential drop is less alarming than it appears, given the exceptionally high prior-quarter base and the maintained margin profile.
The investment case now hinges on execution. The company has the balance sheet strength and industry tailwinds to support its capacity expansion. Success requires translating that market growth into a consistent order book for its significantly larger facilities, moving past quarterly volatility toward sustained scale.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
